Breast Biopsy Devices Market Size To Rise USD 1.52 billion by 2032

Published Date : 02 Aug 2023

The global breast biopsy devices market size surpassed USD 1 billion in 2022 and is projected to rise to USD 1.52 billion by 2032, anticipated to grow at a CAGR of 4.3 percent during the projection period from 2023 to 2032.

Breast Biopsy Devices Market Size and Growth Rate From 2023 To 2032

Medical equipment called as breast biopsy devices are used during breast biopsy procedures. A surgical technique called a breast biopsy involves the removal of tissue or fluid to be inspected and tested for any infections. Under microscopes, the excised tissue is inspected for the presence of cancer. These samples are often transported to testing labs where specialists examine the sample using a variety of instruments and equipment, including needles, tables, wires, and guiding devices. The process of finding sick tissue inside the breast and collecting the specimen sample in the area for any evaluation and identification is known as a breast biopsy. Due of slight discomfort and deformity, minimally invasive biopsy techniques are used to do breast biopsies. Speculative cancer can be diagnosed and treated by doctors with the help of non-invasive biopsy procedures.

This knowledge lessens the complexity of chemo-radiations by preventing the application of therapy in cancer. Unsurprisingly, biopsy operations are frequently carried out using fine-needle aspiration, core needle, and vacuum-assisted breast biopsy equipment (VAB). In order to diagnose breast cancers, a variety of modalities, including ultrasound, diagnostic testing, and resonance imaging, are used as guiding systems. Due to the rise in demand for minimally invasive treatments and non-radiation biopsies, it is projected that the ultrasound industry will see rapid expansion. Breast cancer incidence among women worldwide is steadily rising. A few of the factors influencing the market growth throughout the forecast period include the increase in cancer awareness screening initiatives.

In the United States, 12% of women are predicted to get breast cancer at some point in their lives. Overindulgence in alcoholic beverages, a lack of exercise, poor nutrition and eating habits, severe hormonal imbalances, and excessive sun exposure are factors that contribute to the increase in breast cancer incidence. However, inadequate healthcare infrastructure, particularly in developing nations, and low levels of female population knowledge are limiting the market for breast biopsies from expanding.

The leading players are mostly focusing on technical advancements to boost efficiency. By maintaining the existing development trends and having the necessary financial resources to take part in the most effective methods, this market can experience long-term growth patterns.

Regional Snapshots:

In terms of market share for breast biopsy equipment worldwide in 2021, North America dominated. Due to the increased prevalence of breast cancer, elderly demographics, high healthcare costs, strong economy, and developing private healthcare sector, the use of breast biopsy instruments is notably high in the United States. Additionally, the United States is investing heavily in a variety of medical and health-related research and development activities, which further supports the market expansion in the nation. These institutions include federal-, state-, and local government agencies, voluntary healthcare associations, pharmaceutical and biotechnology companies, professional societies, and research institutions.

The market for breast biopsy devices in APAC is anticipated to grow at the fastest rate, driven by a number of factors including an aging population, an increase in breast cancer cases, increased public awareness of the disease, rising healthcare costs and per capita income, and a surge in research into breast biopsy devices.

Breast Biopsy Devices Market Report Scope:

Report Coverage Details
Market Revenue in 2023 USD 1.04 Billion
Projected Forecast Revenue in 2032 USD 1.52 Billion
Growth Rate from 2023 to 2032 CAGR of 4.3%
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Report Highlights:

  • Over the projected period, the market for breast biopsies is anticipated to expand at a CAGR of about 7.4%. (2022-2029).
  • The market is expected to grow significantly over the coming years as a result of a number of driving factors.
  • According to Guidance, stereotactic breast biopsies are expected to grow significantly throughout the projection period.
  • According to the product, the breast biopsy market is expected to be dominated by the segment of biopsy needles due to the growing acceptability of image-guided procedures in both developed and developing countries.
  • In terms of geography, North America now has a disproportionately large market share and will continue to do so over the projection period.

Market Dynamics:


The global increase in women's susceptibility to mammary cancer, together with screenings and awareness campaigns launched in their favor, are driving the growth of the breast biopsy market. A wide-ranging and active research environment has led to the development of more precise and minimally invasive therapies for the early identification of breast cancer, which has led to the growth of the biopsy market. The development of these diagnostic techniques has benefited from government initiatives to support a stable and comprehensive environment for cancer research.

The health of this industry has also significantly improved thanks to attractive reimbursements. The high market growth over the course of the research period may be attributable to new product approvals and launches as well as a rising demand for needle biopsies that are less invasive and use graphics (such as vacuum-assisted biopsy and core needle biopsy).


Some impoverished nations have subpar medical infrastructure, particularly when it comes to cancer treatments. The lack of qualified surgeons, poor health infrastructure in some nations, and a lack of necessary resources are anticipated to be the biggest obstacles to the growth of the Breast Biopsy market. When compared to the rising cancer occurrences, a recent study indicates that there would be a shortage of about 2300 medical oncologists in the US by the year 2025.

Some of the main constraints hindering the growth of the breast biopsy market include the potential for false negative results and inadequate tissue collection that might render the entire procedure ineffective.


Cancer cell and DNA fragment identification has been difficult in the medical field; however, the development of liquid biopsy has made it possible for doctors to precisely identify circulating tumor cells. Additionally, the method might reduce the need for operations and their negative side effects, such scarring. The liquid biopsy has the ability to detect the whole genetic complexity of tumors seen in human breasts and can also prevent them from metastasizing to other body regions. Such alluring characteristics of the liquid biopsy have created a profitable potential for the expansion of the breast biopsy market as a whole.

Numerous negative outcomes, including significant blood loss, surgical infection, and extended recovery times, have been brought on by the intrusive treatments. However, the introduction of minimally invasive options like image-guided biopsy has produced reliable findings. Breast biopsy market development is anticipated to be driven by the rising acceptance of image-guided needle biopsy over the projected period.


The surgical process used to conduct the biopsy tests has risks, including the possibility of breast bruising, edema, pain, and infection at the site of the operation. The patient may choose to overlook some infection symptoms, such as warmth in the breasts, discharge from the site, redness in the site, or a temperature of more than 100°F, which might worsen the issue. Such elements are impeding the expansion of the breast biopsy market.

Following surgery, certain over-the-counter medications must be avoided, since they may interact negatively with the medicine used during the biopsy. The disease deteriorates if the patient disregards the doctor's recommendations. Such elements are regarded as significant restraints on the market's overall expansion for breast biopsy.

Recent Developments:

  • With the aid of cutting-edge Digital Breast Tomosynthesis technology, Planmed Oy introduced Planmed clarity 3D digital mammography in March 2018 for improved diagnoses, particularly for patients with thick, overlapping breast tissues.

Major Key Players:

  • Cook Medical Incorporated
  • Becton, Dickinson and Company
  •  Devicor Medical Products Inc.
  • C.R. Bard, Inc., Hologic Inc
  • Argon Medical Devices
  • Planmed OY
  • Encapsule Medical Devices LLC
  • Ethicon Endo-Surgery (Johnson and Johnson)

Market Segmentation:

By Product

  • Biopsy Needles
  • Guidance Systems
  • Biopsy Tables
  • Localization Wires
  • Assay Kits
  • Liquid Biopsy Instruments
  • Others

By Guidance

  • Image-Guided Biopsy
  • Mammography-guided Stereotactic Biopsy
  • Ultrasound-guided Biopsy
  • MRI-guided Biopsy
  • Other Guidance Techniques
  • Liquid Biopsy
  • NGS-based Biopsy
  • PCR-based Biopsy
  • Microarray-based Biopsy

By Type

  • Needle Breast Biopsy
  • Core Needle Biopsy (CNB)
  • Fine Needle Aspiration Biopsy (FNAB)
  • Vacuum-assisted Biopsy (VAB)
  • Open Surgical Breast Biopsy
  • Excisional
  • Incisional
  • Liquid Breast Biopsy
  • Circulating Tumor Cells
  • Circulating Tumor DNA (CtDNA)
  • Other Biomarkers

Buy this Research Report@

You can place an order or ask any questions, please feel free to contact at | +1 9197 992 333